Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2results about How to "Little effect on activity" patented technology

Monoclonal antibody dl1 of diariston bacteria and its application

The application discloses a monoclonal antibody DL1 of Dielma bacteria and application thereof, wherein the monoclonal antibody DL1 comprises a DL1 heavy chain and a DL1 light chain, and the monoclonal antibody DL1 is coupled with activated carboxyl magnetic beads to obtain a magnetic bead-antibody conjugate. The magnetic bead-antibody conjugate is used for enrichment, and Dielma bacteria can be enriched to a large extent. The magnetic bead sorting enrichment of Dielma bacteria is selected by using a magnetic force frame, and the method has low cost and small influence on the activity of target bacteria compared with a chip or a flow sorting method. The enriched Dielma bacteria can be applied to the analysis of metabolites of the bacteria, and can also be applied to qualitative or quantitative analysis.
Owner:MEI YI TIAN BIOLOGICAL MEDICINE WUHAN CO LTD

An intracellular imaging system for simultaneously detecting UDG and miR-375 expression levels and its application

PendingCN122081492Aimprove accuracyhigh imaging specificityMicrobiological testing/measurementDNA/RNA fragmentationProstate cancer cellCancer cell
This invention discloses an intracellular imaging system for simultaneously detecting UDG and miR-375 expression levels and its applications. The intracellular imaging system uses a tetrahedral DNA nanostructure as a carrier, loading a HAT-UDG probe with an on / off conformation, and coupling it with a split CRISPR / Cas12a detection component for recognizing miR-375. The split CRISPR / Cas12a detection component includes at least Cas12a protein, scaffold RNA, spacer RNA / equivalent split crRNA components, and a fluorescent reporter substrate. This invention is the first to perform a logical AND operation between two key indicators: UDG enzyme activity and miR-375 expression level. The system can only ultimately trigger a complete fluorescence signal when both are simultaneously highly expressed. This multi-target synergistic activation design constructs a precise molecular recognition logic gate, enabling extremely accurate differentiation between prostate cancer cells (RV-1) and normal cells (293T), as well as other cancer cells (5637) that highly express UDG, fundamentally avoiding misjudgments caused by fluctuations in a single indicator or non-specific expression, resulting in extremely high imaging specificity.
Owner:TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH